cancer underwriting

The global pandemic’s toll on cancer diagnoses and what it may mean for the future of US life expectancy

In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.

In this first interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on general cancer trends, including trends relating to incidence, detection at earlier stages and overdiagnosis.
 

In this, the first of a 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, focuses on how these advances translate into high-level trends, and why they are so important to Life & Health insurance – all in a concise bulleted format, so there’s no need to wade through complex medical descriptions or interpret sensationalized headlines.
 

Dr. Achim Regenauer shares an overview of this important study’s findings and his perspective on the impact on cancer detection and Life & Health insurance.
 

RGA’s consultant oncologist, Dr. Radi Counsell, discusses the ways liquid biopsies will change the face of cancer care, from screening and diagnosis to treatment monitoring and surveillance of survivors. Dr. Counsell also examines underwriting and claims adjudication implications of this emerging technology. 
 

Cancer is an abstract idea in underwriting, until it happens to the underwriter. Get a candid and highly personal perspective, which was first offered at the AHOU 2021 Annual Conference.
 

The improvement in cancer survival rates has led to a growing life insurance need for cancer survivors worldwide. To mark World Cancer Day, Manuel Plisson, SCOR Global Life Head of Inclusive Underwriting & Medical Expertise, discusses an inclusive rating approach that could help address this protection gap.

It sounds a bit flippant, yet it is a request that medical directors and underwriters see quite often.  An informal application or quick quote comes in with a request about “history of brain tumor.”  Or maybe a question of pancreatic cancer.  The underwriter is expected to make an educated guess based on these minimal findings.  All tumors truly aren’t created equal, and people have individualized responses to different abnormalities.  The more information supplied the better chance there is for not only a placeable but a sustainable quote.

Thyroid cancer (TC) is the most prevalent endocrine cancer, accounting for about 95% of all such malignancies. The incidence of this cancer has increased dramatically in the last three decades.